Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Speciality Medicines Limited is a pharmaceutical distribution company engaged in supplying speciality formulations for chronic and complex conditions. The IPO is scheduled to open on 20 March 2026 and close on 24 March 2026. It comprises 23,50,000 shares with an issue size aggregating up to ₹29 crore. The price band is set between ₹117 and ₹124 per share, with a lot size of 1000 shares, and the shares are proposed to be listed on the BSE SME platform.
Speciality Medicines Limited operates in the pharmaceutical distribution segment, focusing on the marketing and supply of speciality formulations used in the treatment of chronic and complex conditions. The company provides products in various dosage forms, including tablets, injections, and inhalers, catering to different therapeutic requirements. Its operations are structured around contract manufacturing for international markets and the distribution of sourced pharmaceutical products within domestic regions. This approach places the company within the broader pharmaceutical supply chain, with exposure to both domestic and overseas markets. The business model includes collaboration with manufacturing partners and a distribution-focused structure, which may influence its positioning within the pharmaceutical market.
The application process for the IPO can be completed through the ASBA facility available via net banking or through a UPI-enabled trading platform. Investors are required to log in, select the IPO section, enter bid details such as the price band and lot size, and confirm the application by authorising the payment mandate. The application amount remains blocked in the bank account until the allotment process is completed, in accordance with applicable guidelines.
For more details, visit the Speciality Medicines Limited IPO page.
Details | Information |
IPO Date | Mar 20, 2026 to Mar 24, 2026 |
Issue Size | 23,50,000 shares (agg. up to ₹29 Cr) |
Price Band | ₹117 to ₹124 per share |
Lot Size | 1000 shares |
Listing At | BSE SME |
Market Maker | Aikyam Capital Private Limited |
Purpose of the IPO
Event | Date |
|---|---|
IPO Open Date | Fri, Mar 20, 2026 |
IPO Close Date | Tue, Mar 24, 2026 |
Tentative Allotment | Wed, Mar 25, 2026 |
Initiation of Refunds | Fri, Mar 27, 2026 |
Credit of Shares to Demat | Fri, Mar 27, 2026 |
Tentative Listing Date | Mon, Mar 30, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Tue, Mar 24, 2026 |
Price Band for the IPO
Minimum Lot Size and Application Details
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,48,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,48,000 |
S-HNI (Min) | 3 | 3,000 | ₹3,72,000 |
S-HNI (Max) | 8 | 8,000 | ₹9,92,000 |
B-HNI (Min) | 9 | 9,000 | ₹11,16,000 |
The Speciality Medicines Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using the broker's app or website.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Speciality Medicines Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (lot size: 1000 shares) within the price band of ₹117 to ₹124 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for Allotment
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Speciality Medicines IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered |
QIB Shares Offered | Not more than 2% of the Net Issue |
Retail Shares Offered | Not less than 49% of Net Issue |
NII Shares Offered | Not less than 49% of Net Issue |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Key Financial Metrics
Recent Performance and Growth Prospects
Potential Risks of Investing in the IPO
Opportunities and Growth Potential
KPI | Oct 31, 2025 | Mar 31, 2025 |
ROE | 18.11% | 37.85% |
ROCE | 16.68% | 33.39% |
Debt/Equity | 0.13 | 0.17 |
RoNW | 16.61% | 28.30% |
PAT Margin | 16.49% | 14.77% |
EBITDA Margin | 17.73% | 15.60% |
Price to Book Value | 2.19 | 2.62 |
Registrar | Lead Manager(s) |
|---|---|
Skyline Financial Services Pvt.Ltd. | Unistone Capital Pvt.Ltd. |
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmedabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: https://www.specialitymedicine.com/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Speciality Medicines IPO allotment status.
Parth Babulal Goyani is the Chairman and Managing Director of Speciality Medicines Ltd.
The Speciality Medicines IPO is scheduled to open for subscription on 20 March 2026 and is set to close on 24 March 2026, as per the disclosed timeline.
The company is engaged in the marketing and distribution of speciality pharmaceutical formulations used in treating chronic and complex conditions. Its business model includes contract manufacturing for international markets and distribution of sourced products domestically. The sustainability of this model depends on factors such as regulatory approvals, supplier relationships, product portfolio expansion, and demand for speciality therapies.
The IPO comprises 23,50,000 shares with an aggregate issue size of up to ₹29 crore, based on the disclosed price band.
‘Pre-apply’ refers to the facility that allows investors to submit their IPO application before the issue opens. The application is processed once the IPO subscription window begins, subject to mandate confirmation.
The lot size for the IPO is 1000 shares. The minimum application for retail investors requires applying for at least two lots, which amounts to 2000 shares.
The tentative allotment date for the IPO is 25 March 2026, as per the provided schedule.
The registrar to the issue is Skyline Financial Services Pvt. Ltd., responsible for handling the allotment and related processes.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
The application process can be completed through the ASBA facility via net banking or through a UPI-enabled trading platform. Investors are required to select the IPO, enter bid details such as price and quantity, and approve the payment mandate within the specified timeline.
Yes, a Demat account is required to apply for the IPO, as shares are credited in electronic form upon allotment.
After the allotment process is completed, applicants can check their allotment status through the registrar’s website or the trading platform used for application. If shares are allotted, they are credited to the Demat account, and any unallocated amount is released as per the applicable process.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading